Does pharmacogenetic testing optimize antidepressant effectiveness in major depressive disorder? Data from a double-blind randomized controlled trial in a real-world clinical setting

Abstract Background Major depressive disorder (MDD) exhibits significant heterogeneity in treatment responses, necessitating multiple pharmacological trials to achieve therapeutic success. Pharmacogenetic (PGx) testing has emerged as a promising tool to personalize antidepressant (AD) treatments, th...

Descripción completa

Detalles Bibliográficos

Autores principales:	Alessandra Minelli, Stefano Barlati, Stefano Bignotti, Valentina Menesello, Gabriele Nibbio, Giulia Perusi, Alessia Muscarella, Lisa Buson, Ughetta Bosco Umbertino, Paolo Martini, Rosana Carvalho Silva, Edoardo Spina, Giovanni Battista Tura, Antonio Vita, Massimo Gennarelli
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Cambridge University Press 2025-01-01
Colección:	European Psychiatry
Materias:	antidepressant treatment depression genetics pharmacogenetic testing randomized controlled trial
Acceso en línea:	https://www.cambridge.org/core/product/identifier/S0924933825101326/type/journal_article
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!